{
  "drugs": [
    {"id": "resmetirom", "class": "THR-beta agonist", "phase": "FDA approved (MASH F2-F3)", "moa": "Hepatic THR-beta selectivity; mitochondrial fat oxidation"},
    {"id": "efruxifermin", "class": "FGF21 analog", "phase": "Phase 3", "moa": "Lipid handling, insulin sensitization, anti-fibrotic"},
    {"id": "pegozafermin", "class": "FGF21 analog", "phase": "Phase 3", "moa": "Lipid metabolism, anti-fibrotic"},
    {"id": "lanifibranor", "class": "Pan-PPAR agonist", "phase": "Phase 3", "moa": "Insulin sensitization, anti-inflammatory, anti-fibrotic"},
    {"id": "semaglutide", "class": "GLP-1 RA", "phase": "Phase 3 (MASH)", "moa": "Weight loss, insulin secretion, indirect hepatic"},
    {"id": "tirzepatide", "class": "GIP/GLP-1 dual", "phase": "Phase 3 (MASH SYNERGY-NASH)", "moa": "Weight loss, insulin sensitization"},
    {"id": "survodutide", "class": "GLP-1/glucagon dual", "phase": "Phase 2/3", "moa": "Hepatic glucagon-mediated lipid oxidation, weight loss"},
    {"id": "pioglitazone", "class": "TZD/PPAR-gamma", "phase": "Off-label MASH", "moa": "Adipocyte sensitization, redistribution"},
    {"id": "vitamin_E", "class": "Antioxidant", "phase": "AASLD recommended (non-diabetic MASH)", "moa": "Reduces oxidative stress"}
  ]
}